📰 Intuitive Surgical Stock Rises on Strong Preliminary Results
Preliminary Q4 revenue jumps 25% to $2.41 billion, driven by surging robotic surgeries and international demand.
Ahead of its presentation at the 2025 J.P. Morgan Healthcare Conference on January 15, Intuitive Surgical ISRG 0.00%↑ reported strong preliminary results for Q4 and full-year 2024, which exceeded Wall Street’s expectations. The company posted a 25% increase in Q4 revenue, reaching approximately $2.41 billion, driven by a rise in procedure volumes and increased demand for its robotic-assisted surgery systems.
For the full year, Intuitive reported a 17% year-over-year revenue increase, totaling $8.35 billion, slightly surpassing the consensus estimate of $8.14 billion. This growth was primarily fueled by an 18% increase in da Vinci procedures in Q4 and a 19% rise in system placements compared to the previous year.
CEO Gary Guthart attributed much of the company’s success to the continued adoption of its latest technologies, including the da Vinci 5 and Ion systems, as well as strong international performance. With the pandemic’s impact on procedures largely behind it, Intuitive expects the momentum to carry into 2025, with further growth in both system placements and procedure volumes.
Despite the impressive preliminary results, the final earnings report for Q4 and full-year 2024 is expected to be released on January 23, 2025, when the company will provide more detailed insights into its performance.
Source: Intuitive Surgical Press Release, Investing.com
Disclaimer:
The information and opinions provided in this article are for informational and educational purposes only and should not be considered as investment advice or a recommendation to buy, sell, or hold any financial product, security, or asset. The Future Investors does not provide personalized investment advice and is not a licensed financial advisor. Always do your own research before making any investment decisions and consult with a qualified financial professional before making any investment decisions. Please consult the general disclaimer for more details.